ABSTRACT Background: The progesterone receptor (PR) is expressed by ∼70% of early breast tumours and is implicated in the progression of breast cancer. In cancerous tissues PR may be activated in the absence of a ligand, or when ligand concentrations are very low, resulting in aberrantly activated PR (APR). The presence of APR may indicate that patients with breast cancer are more likely to respond to antiprogestins. The aims of this study were to describe and classify the histological subnuclear morphology of active and inactive PR in archival breast cancer samples.
INTRODUCTION
Estrogen receptors (ERα) are expressed by ∼75% of human breast cancers. [1] [2] [3] Hormonal therapies, which act by blocking ERα binding or depriving the tumour of estrogen, have become the mainstay of treatment of patients with breast cancer with ERα-positive tumours. 1 2 Progesterone receptor(PR), which is expressed in ∼70% of early breast cancers, has also been implicated in the progression of breast cancer. 2 4 5 Antiprogestins have been shown to have antiproliferative activity in vitro: examples from animal models have shown both antiproliferative and proliferative effects but until now only limited antitumoural activity has been reported in a clinic setting. [5] [6] [7] [8] [9] [10] Gaining a more complete understanding of the actions of PR in breast cancer is of considerable clinical importance for the optimisation of treatment. Despite investigations into the use of antiprogestins to target PR, only onapristone, which is
Key questions
What is already known about this subject?
There is a lack of sufficiently sensitive diagnostics to identify patients with breast cancer who may respond to antiprogestin therapy.
What does this study add?
Immunohistochemistry (IHC) was used to classify the histological subnuclear morphology of activated progesterone receptors (APR) in archival primary breast cancer samples.
How might this impact on clinical practice?
This routine diagnostic IHC technique has the potential to identify patients with APR who may be responsive to antiprogestin therapies, such as onapristone.
currently in clinical development, has demonstrated substantial activity in patients with breast cancer. [9] [10] [11] PR exists in two structurally distinct primary isoforms, PRA and PRB. Both isoforms are transcribed from a single gene but are regulated by two distinct tandem promoters. 12 PRA (97 kDA) is smaller than PRB (120 kDA) because it lacks 164 amino acids at the N-terminus (figure 1). [12] [13] [14] In normal human tissue, the levels of expression of PRA and PRB, within the same cells, are usually comparable. 15 However, the progression of tissue from normal to malignant is reported to be associated with imbalances in the expression of PR isoforms. 15 16 Ligand binding causes PR to undergo a sequence of conformational changes: it dimerises and translocates into the nucleus where it forms a complex with other cofactors. [17] [18] [19] The functional PR complex binds to specific DNA promoter sequences of PR-dependent genes, termed progesterone response elements (PREs). [17] [18] [19] Two subnuclear morphological PR distribution patterns have been previously reported in breast tumours, and are indicative of transcriptional activation status. 20 Using standard, high-magnification microscopy techniques, activated ligand-bound PR can be seen as distinctive foci or in an aggregated (A) pattern. 20 When not bound to a ligand, inactive PR is distributed in a diffuse (D) pattern across the nucleus. This same phenomenon has been observed in a healthy endometrial tissue and endometrial cancer. 21 Post-translational modifications, which include phosphorylation, acetylation, ubiquitination and sumoylation, play roles in PR activation and regulation. 4 9 Phosphorylation promotes PR binding to PREs and association with transcription specificity protein (Sp) factors. PR is known to contain at least 14 phosphorylation sites, which are serine residues concentrated at the N-terminus (figure 1). 13 Kinases such as mitogen activated protein kinase, cyclin A/cyclin-dependent protein kinase 2 and casein kinase II are known to be involved in the phosphorylation process. 13 In cancerous tissues, where kinase activities are often high, PR may be phosphorylated in the absence of a ligand or when ligand concentrations are very low. 4 In addition to increased kinase activity, growth factors may reduce or supplant the need for a progestin ligand, resulting in aberrantly activated PR (APR). 4 Studies have shown that APR is present in a significant number of postmenopausal breast and endometrial tumours. 20 21 Thus, the presence of APR foci/aggregates in breast cancer cells provides a strong rationale for the use of antiprogestins.
We hypothesise that determination of APR could be developed as a diagnostic to identify patients with PR-positive (PR pos ) cancers that are more likely to respond to antiprogestin treatment. Immunohistochemistry (IHC) diagnostic tests to identify the activated forms of steroid receptors were previously described in breast and endometrial cancers. [22] [23] [24] We have developed an IHC-based technique to determine APR status, which is potentially applicable as a routine diagnostic.
In this study we described and classified the histological subnuclear morphology of APR and inactive PR in archival breast cancer samples, using IHC. We also analysed the relationships between APR and antiestrogen treatment outcomes. foci. In the first set of analyses, both IHC and immunofluorescence and confocal microscopy were employed. Both the techniques were found to be concordant (data not shown) so only IHC was used for the remaining analyses.
METHODS Ethics consent and permissions

Analyses
Tumours were deemed PR pos if >1% of tumour cells were stained positive with either PRA or PRB. Tumours with >1% of tumour cells that stained positive with Thermo Scientific SP1 were classified as being ERα-positive (ERα pos ). Ki67 positivity was determined as at least one staining-positive cell using the Dako M7240 reagent, using an internal control (epithelial cells or lymphocytes) to assess the reliability of the Ki67 expression. Staining intensity was ranked on a scale from 0 to 3 (0: no staining; 1: weak intensity, partly specific; 2: moderate intensity; 3: strong intensity figure 3 ), a higher tumour grade ( p=0.046) and a trend for more advanced stage (table 3) . APR pos was associated with a lower staining intensity ( p=0.003) and was independent of HER2 (table 3), ERα and Ki67 (data not shown).
APR was associated with higher grade tumours (table 3). APR was not predictive of outcome with antiestrogens and AIs ( p=0.4). PR pos tumours treated with hormonal therapy had better DFS than the PR-negative tumours (PR neg ; p<0.0001). The results were the same with PRA and PRB (data not shown). This effect was independent of the prognostic effect of ERα. DFS and cumulative progression rate were similar, irrespective of APR status.
DISCUSSION
Most breast cancers express both ERα and PR. In this series of primary breast cancers, stained using specific antibodies for PRA, PRB and ERα, we found that 79% of tumours were PR pos . Of the tumours that were PR pos a significant proportion (30%) were APR pos . APR had a binary mode of expression in the breast cancer specimens tested, which allows the classification of tumours into two subsets. One subset corresponded morphologically to tumours containing cells that express the transcriptionally active form of PR and may indicate tumours suitable for treatment with antiprogestins, such as onapristone.
Previous observations have shown that PR neg tumours are associated with poorer outcomes. 25 As expected, we found that patients with PR pos tumours had a better prognosis than those with PR neg tumours. When individual PR isoforms were examined, we found that the percentage of APR pos tumours were 25% for PRA and 23% for PRB. As reported previously, imbalanced expression of PR isoforms is a common trait of breast and endometrial tumours. 15 16 26-28 The loss of one isoform has been reported in higher histological grades of endometrial cancer. 27 The loss of PRB expression in breast cancer may be explained by phosphorylation-dependent turnover of transcriptionally active PRB compared with the less active and more stable PRA. 4 We observed a small imbalance in tumour expression of PRA and PRB with 5.1% of tumours expressing PRA only and 8.0% of tumours expressing PR (table 2) . These results highlight the importance of using two antibodies instead of one single bispecific antibody, as this has consequences for biomarker positivity. 28 29 There was a trend towards more APR positivity among patients with more advanced stages of breast cancer. This trend was more evident with the PRB isoform compared with PRA ( p=0.040 vs p=0.18). APR pos was also associated with both the per cent and intensity of PR cell-positive staining. In this series of breast cancer samples, APR status was independent of the per cent of tumour cells expressing ERα, Ki67 and HER2. This suggests that targeting APR, using a therapy with a distinct mechanism of action compared with the currently available therapies, has the potential for independent treatment benefits and should not be cross-resistant.
The development of therapies that target tumours expressing hormones and other receptors including ERα and HER2 has transformed treatment outcomes for patients with breast cancer. Recent studies have renewed interest in the potential of PR as an independent target for treatment with antiprogestins, such as onapristone. A routine diagnostic technique for identifying patients who are likely to respond to antiprogestin therapy would be a major advantage. Regular immunofluorescence and confocal microscopy are not practical for identifying APR on a routine clinical basis. We have developed a generalisable diagnostic technique to identify APR in endometrial and breast tumours. The diagnostic development plan has been reviewed by the regulatory authorities and will be moving forward as part of the registration strategy for the development of onapristone. This technology has now been migrated onto a Contributors JBon provided archived tumour samples and clinical information from the clinical centre. JBos provided central pathology review and read development. PJ provided technical method development and execution. AV provided technical method development and execution. EMG was the concept originator and provided scientific direction and statistical analyses. AAZ provided sponsorship, strategic scientific input and direction of companion diagnostic development (APR test). SAWF provided scientific guidance in design, data review and interpretation. CAL provided design input, data review, data interpretation and guidance on presentation. JO provided disease area expertise in design and execution, advice and guidance during execution, data review and interpretation, and guidance on presentation.
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